131 related articles for article (PubMed ID: 37160252)
21. Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(14):1-148. PubMed ID: 33240455
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
23. Routine real-time cost-effectiveness monitoring of a web-based depression intervention: a risk-sharing proposal.
Naveršnik K; Mrhar A
J Med Internet Res; 2014 Feb; 16(2):e67. PubMed ID: 24583773
[TBL] [Abstract][Full Text] [Related]
24. Illustration of a Method to Incorporate Preference Uncertainty in Benefit-Cost Analysis.
Baik S; Davis AL; Morgan MG
Risk Anal; 2019 Nov; 39(11):2359-2368. PubMed ID: 31136683
[TBL] [Abstract][Full Text] [Related]
25. Analysing risk attitudes to time.
Oliver A; Cookson R
Health Econ; 2010 Jun; 19(6):644-55. PubMed ID: 19424992
[TBL] [Abstract][Full Text] [Related]
26. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
Devlin N; Parkin D
Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
[TBL] [Abstract][Full Text] [Related]
27. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
28. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
Chen G; Peirce V; Marsh W
Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
Konnopka A; Conrad K; Baerwald C; König HH
Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304
[TBL] [Abstract][Full Text] [Related]
31. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
32. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
[TBL] [Abstract][Full Text] [Related]
33. Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.
Guzauskas GF; Basu A; Carlson JJ; Veenstra DL
Value Health; 2019 Sep; 22(9):988-994. PubMed ID: 31511188
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information.
Campbell JD; McQueen RB; Libby AM; Spackman DE; Carlson JJ; Briggs A
Med Decis Making; 2015 Jul; 35(5):596-607. PubMed ID: 25349188
[TBL] [Abstract][Full Text] [Related]
35. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
36. Calculating when elective abdominal aortic aneurysm repair improves survival for individual patients: development of the Aneurysm Repair Decision Aid and economic evaluation.
Grant SW; Sperrin M; Carlson E; Chinai N; Ntais D; Hamilton M; Dunn G; Buchan I; Davies L; McCollum CN
Health Technol Assess; 2015 Apr; 19(32):1-154, v-vi. PubMed ID: 25924187
[TBL] [Abstract][Full Text] [Related]
37. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment.
Lomas JRS
Value Health; 2019 Aug; 22(8):898-905. PubMed ID: 31426931
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
39. QALYs and ambulatory status: societal preferences for healthcare decision making.
Freath LL; Curry AS; Cork DMW; Audhya IF; Gooch KL
J Med Econ; 2022; 25(1):888-893. PubMed ID: 35713217
[TBL] [Abstract][Full Text] [Related]
40. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.
Edney LC; Haji Ali Afzali H; Cheng TC; Karnon J
Pharmacoeconomics; 2018 Feb; 36(2):239-252. PubMed ID: 29273843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
